Efficacy assessment
toxicity, PD, SD
DISEASE PROGRESSION, DISEASE, CENTRAL NERVOUS SYSTEM TUMORS, SOLID TUMORS
Radiographic assessments were conducted at screening and at the end of the DLT observation period and repeated every six weeks during the extended treatment period until disease progression, intolerable toxicity, or withdrawal of consent (whichever came first). The patients with central nervous system tumors were evaluated for responses according to the RANO criteria by enhanced magnetic resonance imaging (MRI) scan. Patients with other solid tumors were assessed by computed tomography (CT) or MRI scan according to RECIST version 1.1. The categories used for the evaluation of the response to treatment included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). ORR and DCR were defined as CR + PR and CR + PR + SD, respectively.